Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
afc2881
afc2881 Jun. 5 at 5:31 AM
$BCLI https://x.com/i/status/2062377086447124883
0 · Reply
afc2881
afc2881 Jun. 5 at 5:24 AM
$BCLI DoctorJT, Idk what rock u been living under, but in case u don't know, there has been a changing of the guard at Fda. More flexibility in rare disease platforms is being highlighted as a new direction for future approvals. The cp sits front & center in front of this flexibility. As mentioned in an earlier post, I also believe we are more derisked now than ever before because of the new landscape we are in now. Nurown will prevail.
1 · Reply
DoctorJT
DoctorJT Jun. 5 at 4:31 AM
$BCLI I think people here are blind and being very naive about the CP. I hope for pals and longs alike, I’m wrong, but the best pulse is Michelle. She is indeed in the know. Doesn’t get any clearer than this post below. She straight up said the FDA has provided no updates since the cookie cutter letter in December. https://x.com/avoice4als/status/2061963393012306296?s=46
1 · Reply
Condo3e
Condo3e Jun. 4 at 6:59 PM
$BCLI The motivation should only focus itself on the ALS patients at this stage of the process.
2 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 4 at 3:09 PM
$BCLI Crazy to think about it this way but we are probably closer to approval (and more derisked) now at .80 cents than we were at 18 dollars.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 4 at 2:21 PM
$BCLI Looks like the CEO Chaim Lebovits loaded with stock too! Chaim and Peter very incentivized to get NurOwn across the finish line and achieve accelerated approval for patients! Come on Peter and Chaim let's get NurOwn into bodies like yesterday already please!!!
1 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 4 at 2:12 PM
$BCLI Looks like they just loaded new Board of Director Former FDA Associate Commissioner Peter Pitts up with a large stock option to get this done and to get NurOwn across the finish line!
0 · Reply
Condo3e
Condo3e Jun. 4 at 1:53 PM
$BCLI For the hopes of ALS patients, it's way past due for positive action with dollars for NurOwn.
0 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 4 at 3:44 AM
$BCLI What a find by some of the peeps in the Huntingtons community. Updated today before the closed door FDA meeting. CBER now has showcased precedent documenting the use of RWE as substantial evidence for approval. Even using Natural history studies as a basis for approval. Proof that the previous FDA Decision to declare substantial evidence for NurOwn was a sham. Not sure how this doesn’t get approved now. Wow. https://www.fda.gov/science-research/real-world-evidence/cber-biological-product-approvals-used-real-world-evidence
2 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 3 at 8:34 PM
$BCLI Sounds like things went well with FDA!
1 · Reply
Latest News on BCLI
No data available.
afc2881
afc2881 Jun. 5 at 5:31 AM
$BCLI https://x.com/i/status/2062377086447124883
0 · Reply
afc2881
afc2881 Jun. 5 at 5:24 AM
$BCLI DoctorJT, Idk what rock u been living under, but in case u don't know, there has been a changing of the guard at Fda. More flexibility in rare disease platforms is being highlighted as a new direction for future approvals. The cp sits front & center in front of this flexibility. As mentioned in an earlier post, I also believe we are more derisked now than ever before because of the new landscape we are in now. Nurown will prevail.
1 · Reply
DoctorJT
DoctorJT Jun. 5 at 4:31 AM
$BCLI I think people here are blind and being very naive about the CP. I hope for pals and longs alike, I’m wrong, but the best pulse is Michelle. She is indeed in the know. Doesn’t get any clearer than this post below. She straight up said the FDA has provided no updates since the cookie cutter letter in December. https://x.com/avoice4als/status/2061963393012306296?s=46
1 · Reply
Condo3e
Condo3e Jun. 4 at 6:59 PM
$BCLI The motivation should only focus itself on the ALS patients at this stage of the process.
2 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 4 at 3:09 PM
$BCLI Crazy to think about it this way but we are probably closer to approval (and more derisked) now at .80 cents than we were at 18 dollars.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 4 at 2:21 PM
$BCLI Looks like the CEO Chaim Lebovits loaded with stock too! Chaim and Peter very incentivized to get NurOwn across the finish line and achieve accelerated approval for patients! Come on Peter and Chaim let's get NurOwn into bodies like yesterday already please!!!
1 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 4 at 2:12 PM
$BCLI Looks like they just loaded new Board of Director Former FDA Associate Commissioner Peter Pitts up with a large stock option to get this done and to get NurOwn across the finish line!
0 · Reply
Condo3e
Condo3e Jun. 4 at 1:53 PM
$BCLI For the hopes of ALS patients, it's way past due for positive action with dollars for NurOwn.
0 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 4 at 3:44 AM
$BCLI What a find by some of the peeps in the Huntingtons community. Updated today before the closed door FDA meeting. CBER now has showcased precedent documenting the use of RWE as substantial evidence for approval. Even using Natural history studies as a basis for approval. Proof that the previous FDA Decision to declare substantial evidence for NurOwn was a sham. Not sure how this doesn’t get approved now. Wow. https://www.fda.gov/science-research/real-world-evidence/cber-biological-product-approvals-used-real-world-evidence
2 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 3 at 8:34 PM
$BCLI Sounds like things went well with FDA!
1 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 3 at 6:26 PM
$BCLI iamals is meeting with FDA behind closed doors this afternoon with the acting commissioner regarding rare disease treatments. ALS Association is NOT involved.
2 · Reply
HUMBL4Now
HUMBL4Now Jun. 3 at 5:50 PM
$BCLI it feels like there is some magic in the air here for the first time in a long time
1 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 3 at 3:19 PM
$BCLI extremely confident this pops over a dollar short term. There have been some very positive developments within and outside the FDA that make me think NurOwn is getting a second look. I expect the CP to get approval. That will bring funding to the P3B.
1 · Reply
Pipemajors82
Pipemajors82 Jun. 3 at 12:04 PM
$BCLI https://www.facebook.com/share/v/1DBBXJ1GMU/
0 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 2 at 7:29 PM
$BCLI Pitts seems to be all in on NurOwn and the science and Chaim seems very confident in funding and the Phase 3b trial starting! LET'S GO!!! https://www.biospace.com/drug-development/brainstorm-levels-up-bringing-on-former-fda-leader-peter-pitts-for-new-als-bid?shem=rimspwouoe
1 · Reply
Condo3e
Condo3e Jun. 2 at 1:28 AM
$BCLI Since shares were issued to Brainstorm folks on May 29, the stock will likely move higher from here.
0 · Reply
jstnfstr
jstnfstr Jun. 1 at 6:10 PM
$BCLI On the one hand, the evident volume increase and higher occasional price points reflect, as per Pitts’decision to join, increasing confidence in the company’s potential, if not viability. On the other hand, recent financing in the $.60s, etc., have produced a new supply of shares evidently being sold into the last days’ buying. Otherwise, I think today’s 40k vol ( so far) would have pushed SP into the $.90s ( where it was recently). Will be interesting to see if a Form 4 in the couple of days might reveal some modest purchases by Pitts demonstrating his level of confidence.
2 · Reply
Condo3e
Condo3e Jun. 1 at 12:26 AM
$BCLI It's been almost 3 years since the NurOwn Adcom, and since then certain postive non monetary advances have been made to continue development of NurOwn, however without a significant influx of cash onto the Brainstorm balance sheet, NurOwn remains parked and unavailable for those who could see a positive benefit if treated with the therapy.
0 · Reply
AshvsEvilDead
AshvsEvilDead May. 31 at 10:04 PM
$BCLI A lot to unpack here but Pitts already making significant contributions and calls out NurOwn Directly. https://publichealth.realclearjournals.org/perspectives/2026/05/restoring-regulatory-fairness-and-reclaiming-biomedical-leadership-als-rare-disease-regulation-and-the-future-of-regenerative-medicine/
2 · Reply
Pipemajors82
Pipemajors82 May. 31 at 1:18 PM
$BCLI this week will be 11 months. Lot of shakeups in FDA. Not a peep from Chiam except new former FDA official hire. We should here something before July 1st. Im assuming the CP principals have been talking to FDA?
1 · Reply
neuroinvestor3
neuroinvestor3 May. 29 at 11:12 AM
$CLNN wouldn't be a bad idea to get a former FDA person on the Clene BOD like $BCLI just did….https://ir.brainstorm-cell.com/2026-05-28-BrainStorm-Cell-Therapeutics-Appoints-Former-FDA-Associate-Commissioner-Peter-J-Pitts-to-Board-of-Directors
0 · Reply
afc2881
afc2881 May. 28 at 8:55 PM
$BCLI Condo I sure would like Chaim to use the leverage he has with the exosome technology into the funds to cover the ph3b trial. Its time to get the train moving out of the station!
2 · Reply